Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Observational Study to Evaluate Ocular Disease Progression in Children With CLN2 Batten Disease

NCT04462692 is registered in ClinicalTrials.gov with REGENXBIO Inc. as lead sponsor.

NCT NCT04462692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04462692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Observational Study to Evaluate Ocular Disease Progression in Children With CLN2 Batten Disease
Lead sponsor
REGENXBIO Inc.
Phase
Observational
Overall status
Withdrawn
Start date
March 31, 2021
Completion date
October 31, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neuronal ceroid lipofuscinosis type 2 (cln2)